TISIDB

Summary
Symbol	LRRC8A
Name	leucine rich repeat containing 8 family, member A
Aliases	KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location	9q34.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Multi-pass membrane protein Note=The leucine-rich repeat (LRR) domain is on the cytoplasmic side of the cell membrane.
Domain	PF13855 Leucine rich repeat PF12534 Pannexin-like TM region of LRRC8
Function	Essential component of the volume-regulated anion channel (VRAC, also named VSOAC channel), an anion channel required to maintain a constant cell volume in response to extracellular or intracellular osmotic changes. The VRAC channel conducts iodide better than chloride and may also conduct organic osmolytes like taurine (PubMed:24725410, PubMed:24790029, PubMed:26530471, PubMed:26824658). LRRC8A and LRRC8D are required for the uptake of the drug cisplatin (PubMed:26530471). Required for in vivo channel activity, together with at least one other family member (LRRC8B, LRRC8C, LRRC8D or LRRC8E); channel characteristics depend on the precise subunit composition (PubMed:24790029, PubMed:26824658). Can form functional channels by itself (in vitro) (PubMed:26824658). Involved in B-cell development: required for the pro-B cell to pre-B cell transition (PubMed:14660746). Also required for T-cell development (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0002327 immature B cell differentiation GO:0002329 pre-B cell differentiation GO:0002521 leukocyte differentiation GO:0006820 anion transport GO:0006884 cell volume homeostasis GO:0006970 response to osmotic stress GO:0008361 regulation of cell size GO:0030098 lymphocyte differentiation GO:0030183 B cell differentiation GO:0032535 regulation of cellular component size GO:0042113 B cell activation GO:0044070 regulation of anion transport GO:0090066 regulation of anatomical structure size GO:0098656 anion transmembrane transport
Molecular Function	GO:0005216 ion channel activity GO:0005225 volume-sensitive anion channel activity GO:0005253 anion channel activity GO:0008509 anion transmembrane transporter activity GO:0015267 channel activity GO:0022803 passive transmembrane transporter activity GO:0022838 substrate-specific channel activity
Cellular Component	GO:0034702 ion channel complex GO:1902495 transmembrane transporter complex GO:1990351 transporter complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	LRRC8A
Name	leucine rich repeat containing 8 family, member A
Aliases	KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location	9q34.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between LRRC8A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	LRRC8A
Name	leucine rich repeat containing 8 family, member A
Aliases	KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location	9q34.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of LRRC8A in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: 0.91; FDR: 0.032300	Sensitive to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	LRRC8A
Name	leucine rich repeat containing 8 family, member A
Aliases	KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location	9q34.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of LRRC8A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.138	0.562
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.333	0.862
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.005	0.997
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.064	0.818
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.26	0.903
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.191	0.947
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.443	0.242
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.388	0.788
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.461	0.782
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.46	0.723
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.108	0.538
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.299	0.003

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of LRRC8A in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	0	9.5	0.492
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	0	15.4	0.482
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	11.1	8.9	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	LRRC8A
Name	leucine rich repeat containing 8 family, member A
Aliases	KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location	9q34.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LRRC8A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	LRRC8A
Name	leucine rich repeat containing 8 family, member A
Aliases	KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location	9q34.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LRRC8A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LRRC8A. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	LRRC8A
Name	leucine rich repeat containing 8 family, member A
Aliases	KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location	9q34.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LRRC8A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	LRRC8A
Name	leucine rich repeat containing 8 family, member A
Aliases	KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location	9q34.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of LRRC8A expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	LRRC8A
Name	leucine rich repeat containing 8 family, member A
Aliases	KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location	9q34.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between LRRC8A and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	LRRC8A
Name	leucine rich repeat containing 8 family, member A
Aliases	KIAA1437; FLJ10337; SWELL1; LRRC8; leucine rich repeat containing 8; AGM5; leucine-rich repeat-containing pr ......
Chromosomal Location	9q34.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting LRRC8A collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse LRRC8A